Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Public- versus private-sector research: what do they bring to the table?  Editorial  How important is the contribution of public-sector or academic research to the development of new medicines? In comparison with research conducted in the private sector by pharmaceutical companies, does it lead to more drugs that represent a therapeutic advance? Full article available for download (FREE) 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Exagamglogene autotemcel (Casgevy°) in beta-thalassaemia or sickle-cell disease  Marketing Authorisations  Exagamglogene autotemcel is the first gene therapy product using the CRISPR-Cas9 system to have been granted marketing authorisation in the European Union. It is indicated in certain patients with severe forms of beta-thalassaemia or sickle-cell disease. Is it curative in these patients? Does it eliminate the need for blood transfusions and iron chelators in severe beta-thalassaemia, does it eliminate vaso-occlusive crises and their complications in sickle-cell disease, and what are its adverse effects? Full article (4 pages) available for download by subscribers 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Ritlecitinib (Litfulo°) in severe alopecia areata in adults and adolescents  Marketing Authorisations  Ritlecitinib is an immunosuppressant that inhibits various kinases, including Janus kinases. It has been authorised in the European Union for the treatment of adults and adolescents with severe alopecia areata. Full article available for download by subscribers 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Children exposed to progestogens in utero: excess cancers?  Adverse Effects  In June 2024, the European pharmacovigilance committee (PRAC) recommended that marketing authorisation for products containing hydroxyprogesterone should be suspended, due to the lack of proven efficacy in preventing preterm birth and the risk of cancer in children exposed in utero. Other progestogens, including progesterone, are authorised for the prevention of spontaneous abortion early in pregnancy. What are the main data concerning the risk of cancer in children exposed to a progestogen in utero? Full article available for download by subscribers 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Anticoagulants and heavy menstrual bleeding  Adverse Effects  According to 2 cohort studies published in 2022 and 2023, 2 out of 3 women under 50 years of age on anticoagulant treatment for venous thromboembolism or pulmonary embolism have troublesome heavy menstrual bleeding, with sometimes major consequences for their everyday lives. In this situation, the insertion of an intrauterine device containing levonorgestrel usually reduces the volume of menstrual blood loss, with largely acceptable adverse effects. Full article available for download by subscribers 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Errors related to brand names: the EMA can still do more  Advancing Healthcare Policy  In March 2022, Prescrire responded to a public consultation launched by the European Medicines Agency (EMA) in preparation for the 7th revision of its guideline on the acceptability of brand names for drugs authorised via the centralised procedure. The new version of this guideline was published in December 2023. For drugs that are the subject of a European marketing authorisation application, the EMA is stepping up its efforts to prevent medication errors related to brand names. But it still does not encourage systematic use of international nonproprietary names. Full article (3 pages) available for download (FREE) 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON•  Fexinidazole in sleeping sickness caused by Trypanosoma brucei rhodesiense • Esketamine in depression: new data • SSRI antidepressants and venlafaxine: increased risk of injuries • Pharmaceutical companies on trial > Subscribe now 1 March 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn and Facebook Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn or > Follow us on Facebook 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2025 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---